HK1197065A1 - New process for the preparation of crystal modifications for use in the preparation of esomeprazole sodium salt - Google Patents

New process for the preparation of crystal modifications for use in the preparation of esomeprazole sodium salt

Info

Publication number
HK1197065A1
HK1197065A1 HK14110572A HK14110572A HK1197065A1 HK 1197065 A1 HK1197065 A1 HK 1197065A1 HK 14110572 A HK14110572 A HK 14110572A HK 14110572 A HK14110572 A HK 14110572A HK 1197065 A1 HK1197065 A1 HK 1197065A1
Authority
HK
Hong Kong
Prior art keywords
preparation
sodium salt
new process
crystal modifications
esomeprazole sodium
Prior art date
Application number
HK14110572A
Other languages
English (en)
Chinese (zh)
Inventor
Martin Bohlin
Ursula Pettersson
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of HK1197065A1 publication Critical patent/HK1197065A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
HK14110572A 2004-06-24 2014-10-23 New process for the preparation of crystal modifications for use in the preparation of esomeprazole sodium salt HK1197065A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US58261704P 2004-06-24 2004-06-24

Publications (1)

Publication Number Publication Date
HK1197065A1 true HK1197065A1 (en) 2015-01-02

Family

ID=35782078

Family Applications (1)

Application Number Title Priority Date Filing Date
HK14110572A HK1197065A1 (en) 2004-06-24 2014-10-23 New process for the preparation of crystal modifications for use in the preparation of esomeprazole sodium salt

Country Status (12)

Country Link
US (1) US8658799B2 (xx)
EP (1) EP1765806A1 (xx)
JP (2) JP5457632B2 (xx)
KR (2) KR20130140918A (xx)
CN (3) CN103772360A (xx)
AU (1) AU2005257709C1 (xx)
BR (1) BRPI0512522A (xx)
CA (1) CA2570795C (xx)
HK (1) HK1197065A1 (xx)
MX (1) MXPA06015031A (xx)
NZ (1) NZ551970A (xx)
WO (1) WO2006001753A1 (xx)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1907375B1 (en) * 2005-06-08 2013-07-24 LEK Pharmaceuticals d.d. Crystalline solvate of omeprazole sodium
WO2007055178A1 (ja) * 2005-11-08 2007-05-18 Japan Health Sciences Foundation 細胞の分取方法、及び当該方法に用いる基材
US8063074B2 (en) 2006-05-04 2011-11-22 Dr. Reddy's Laboratories Limited Polymorphic forms of esomeprazole sodium
EP2143722A1 (en) 2008-07-09 2010-01-13 Lek Pharmaceuticals D.D. Process for preparation of esomeprazole sodium of high chemical purity and new forms of esomeprazole sodium
CA2789298A1 (en) 2010-02-12 2011-08-18 Esteve Quimica, S.A. Preparation process of the sodium salt of esomeprazole
CN102746272B (zh) * 2012-04-11 2014-06-25 江苏奥赛康药业股份有限公司 一种埃索美拉唑钠多晶型物及其制备方法和应用
CN102746273A (zh) * 2012-05-29 2012-10-24 江苏奥赛康药业股份有限公司 一种埃索美拉唑钠多晶型物及其在注射用药物中的应用
CN104031032B (zh) * 2014-07-04 2016-04-27 江苏奥赛康药业股份有限公司 一种埃索美拉唑钠化合物及其药物组合物

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4378974A (en) * 1982-06-09 1983-04-05 Allis-Chalmers Corporation Start-up method for coal gasification plant
SE8301182D0 (sv) 1983-03-04 1983-03-04 Haessle Ab Novel compounds
NZ244301A (en) 1991-09-20 1994-08-26 Merck & Co Inc Preparation of 2-pyridylmethylsulphinylbenzimidazole and pyridoimidazole derivatives from the corresponding sulphenyl compounds
SE9301830D0 (sv) 1993-05-28 1993-05-28 Ab Astra New compounds
US6875872B1 (en) * 1993-05-28 2005-04-05 Astrazeneca Compounds
WO1995032957A1 (en) * 1994-05-27 1995-12-07 Astra Aktiebolag Novel ethoxycarbonyloxymethyl derivatives of substituted benzimidazoles
SE504459C2 (sv) 1994-07-15 1997-02-17 Astra Ab Förfarande för framställning av substituerade sulfoxider
SE510666C2 (sv) * 1996-12-20 1999-06-14 Astra Ab Nya Kristallmodifikationer
SE510650C2 (sv) * 1997-05-30 1999-06-14 Astra Ab Ny förening
SE510643C2 (sv) * 1997-06-27 1999-06-14 Astra Ab Termodynamiskt stabil omeprazol natrium form B
NL1007699C2 (nl) 1997-12-04 1999-06-09 Medisize Bv Beademingssysteem.
SE9900274D0 (sv) * 1999-01-28 1999-01-28 Astra Ab New compound
RO122491B1 (ro) * 1999-08-26 2009-07-30 Applied Analytical Industries, Inc. Derivaţi de benzimidazol, alcoxi substituiţi, compoziţii farmaceutice care îi conţin şi utilizarea acestora
CA2775616C (en) 2000-08-04 2013-09-17 Takeda Pharmaceutical Company Limited Salts of benzimidazole compound and application thereof
WO2003089408A2 (en) 2002-04-22 2003-10-30 Sun Pharmaceutical Industries Limited Optically active substituted pyridinylmethyl-sulphinyl-benzimidazole and salts
WO2004002982A2 (en) 2002-06-27 2004-01-08 Dr. Reddy's Laboratories Limited A process for preparation of optically pure or optically enriched sulfoxide compounds, including amorphous esomeprazole and salts thereof
EA200500673A1 (ru) 2002-10-22 2005-12-29 Рэнбакси Лабораториз Лимитед Аморфная форма соли эзомепразола, способ ее получения и фармацевтическая композиция на её основе
US7452998B2 (en) * 2002-12-06 2008-11-18 Nycomed Gmbh Process for preparing optically pure active compounds
WO2004089935A1 (en) * 2003-04-10 2004-10-21 Hetero Drugs Limitd Novel crystalline forms of s-omeprazole magnesium
MXPA05013316A (es) 2003-06-10 2006-03-17 Teva Pharma Proceso para preparar bencimidazoles 2[-(piridinil)metil]sulfinil-sustituidos y derivados clorados novedosos de pantoprazol.

Also Published As

Publication number Publication date
JP2008503574A (ja) 2008-02-07
CN1972928A (zh) 2007-05-30
JP2012246316A (ja) 2012-12-13
US20080039503A1 (en) 2008-02-14
MXPA06015031A (es) 2007-02-08
KR20130038949A (ko) 2013-04-18
JP5457632B2 (ja) 2014-04-02
AU2005257709A1 (en) 2006-01-05
EP1765806A1 (en) 2007-03-28
WO2006001753A1 (en) 2006-01-05
US8658799B2 (en) 2014-02-25
BRPI0512522A (pt) 2008-03-11
NZ551970A (en) 2010-01-29
AU2005257709C1 (en) 2011-02-24
AU2005257709B2 (en) 2008-11-13
KR20130140918A (ko) 2013-12-24
CA2570795A1 (en) 2006-01-05
CA2570795C (en) 2013-05-28
CN103121992A (zh) 2013-05-29
CN103772360A (zh) 2014-05-07

Similar Documents

Publication Publication Date Title
HK1197065A1 (en) New process for the preparation of crystal modifications for use in the preparation of esomeprazole sodium salt
IL190137A0 (en) Crystals of laquinimod sodium, and process for the manufacture thereof
HK1109736A1 (en) Sodium meta-arsenite for use in the treatment of metastatic neoplastic diseases
IL186349A0 (en) Preparation and use of aryl alkyl acid derivatives for the treatment of obesity
IL192241A (en) A process for making 4 - (benzimidazolylmethylamino) - benzamides and their salts
ZA201000219B (en) Methods and compounds useful for the preparation of sodium glucose co-transporter 2 inhibitors
IL182693A0 (en) Methods of preparing indazole compounds
IL175605A0 (en) Controlled release of topirimate in liquid dosage forms
ZA200702977B (en) Methods of preparing indazole compounds
EP1984327A4 (en) IMPROVED METHOD FOR THE PRODUCTION OF CILASTATIN AND ITS SODIUM SALT
GB2436262B (en) Process for the preparation of pantoprazole sodium
ZA200701016B (en) Process for the preparation of isothiazole derivatives
PL1753720T3 (pl) Proces wytwarzania peryndoprylu i jego soli
EP1757282A4 (en) USE OF KAURANE COMPOUNDS IN THE MANUFACTURE OF MEDICAMENTS
IL182353A0 (en) Methods using glycosaminoglycans for the treatment of kidney disease
HUP0401379A2 (en) Process for the preparation of risperidon
GB0516610D0 (en) Compounds for use in therapy
ZA200610483B (en) Process for the preparation of nateglinide
GB0513546D0 (en) Therapeutic compounds and methods for their preparation and use
GB0425532D0 (en) Therapeutic compounds and methods for their preparation and use
HK1125634A1 (en) Pharmaceutical for use in the treatment of ureterolithiasis
HUP0402163A2 (en) Process for the preparation of risperidone
GB0427826D0 (en) Compounds for use in therapy
GB0423117D0 (en) Compounds for use in therapy
SI1732916T1 (sl) Postopek za pripravo alkoksikarbonilmetoksi-ciklopentanov